Domača stran500124 • BOM
Dr Reddy's Laboratories Ltd
1339,20 ₹
15. jan., 16:01:38 GMT +5.30 · INR · BOM · Izjava
DelnicaVrednostni papir, ki kotira v INSedež podjetja: IN
Prejšnji trg. dan.
1337,30 ₹
Dnevni razpon
1314,90 ₹ - 1345,80 ₹
Letni razpon
1104,69 ₹ - 1420,20 ₹
Tržna kapitalizacija
1,12 bil. INR
Povprečni obseg
95,25 tis.
Razm. P/E
20,91
Dividendna donosnost
0,60 %
Primarna borza
NSE
Ocena za podnebje CDP
A-
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
(INR)sep. 2024Sprememba L/L
Prihodek
80,16 mrd.16,51 %
Stroški poslovanja
29,72 mrd.24,54 %
Čisti dohodek
12,55 mrd.−15,18 %
Čista dobičkovnost prihodkov
15,66−27,20 %
Earnings per share
15,83−11,13 %
EBITDA
22,02 mrd.8,53 %
Efektivna davčna stopnja
30,01 %
Skupna sredstva
Skupne obveznosti
(INR)sep. 2024Sprememba L/L
Denar. in kratkor. naložbe
63,07 mrd.−7,15 %
Skupna sredstva
465,96 mrd.34,27 %
Skupne obveznosti
156,67 mrd.66,79 %
Celoten lastniški kapital
309,28 mrd.
Shares outstanding
833,05 mio.
Razmerje P/B
3,65
Donosnost sredstev
10,24 %
Donosnost kapitala
13,21 %
Neto sprememba denarnih sredstev
(INR)sep. 2024Sprememba L/L
Čisti dohodek
12,55 mrd.−15,18 %
Denar iz dejavnosti
9,32 mrd.−48,03 %
Denar iz naložb
−19,07 mrd.−322,21 %
Denar iz financiranja
16,15 mrd.329,53 %
Neto sprememba denarnih sredstev
6,37 mrd.1,03 %
Prost denarni tok
3,92 mrd.−72,47 %
Vizitka
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr. Wikipedia
Generalni direktor
Datum ustanovitve
1984
Spletno mesto
Zaposleni
27.048
Iskanje
Počisti iskanje
Zapiranje iskanja
Googlove aplikacije
Glavni meni